29 April 2025, Mumbai: IOL Chemicals and Pharmaceuticals Limited (IOL), a leading manufacturer of pharmaceutical (APIs) and specialty chemicals, announced that it has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products istration (NMPA), China, for its product Ibuprofen. This approval authorizes the Company to export its Ibuprofen API to the Chinese market.
Ibuprofen is a widely used non-steroidal anti-inflammatory drug (NSAID) known for its effectiveness in relieving pain, reducing inflammation, and lowering fever. With this certification, IOL will be able to cater to the growing demand for high-quality APIs in China, further strengthening its global footprint.
IOL maintains a diversified portfolio of more than 13 APIs, including Metformin Hydrochloride, Clopidogrel Bisulfate Form II, Pantoprazole Sodium, Losartan Potassium, among others. The Company remains committed to expanding its international reach through quality manufacturing and regulatory excellence.
